Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
申请人:Institut National de la Sante et de la Recherche Medicale (INSERM)
公开号:US10426758B2
公开(公告)日:2019-10-01
The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
本发明涉及以下通式(I)的化合物或其药学上可接受的盐和/或溶液,用作细胞坏死抑制剂。本发明还涉及一种药物组合物,其包含通式(I)的化合物或其药学上可接受的盐和/或溶液,用于预防和/或治疗与细胞坏死相关的疾病。本发明还包括通式(I)化合物用于器官保存的用途。